The application of JAK inhibitors in the peri-transplantation period of hematopoietic stem cell transplantation for myelofibrosis

被引:1
作者
Wang, Zerong [1 ]
Jin, Xuelian [1 ]
Zeng, Jiajia [1 ]
Xiong, Zilin [1 ]
Chen, Xinchuan [1 ]
机构
[1] Sichuan Univ, West China Hosp, Chengdu, Sichuan, Peoples R China
关键词
Myelofibrosis; JAK inhibitors; Ruxolitinib; Allogeneic hematopoietic stem cell transplantation; Poor implantation; Graft-versus-host disease; GANDOTINIB LY2784544; COMFORT-II; RUXOLITINIB; OUTCOMES; SAFETY; DISEASE; PACRITINIB; FEDRATINIB; EFFICACY; THERAPY;
D O I
10.1007/s00277-024-05703-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN) with a poor prognosis, and allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only treatment with curative potential. Ruxolitinib, a JAK1/2 inhibitor, has shown promising results in improving patients' symptoms, overall survival, and quality of life, and can be used as a bridging therapy to HSCT that increases the proportion of transplantable patients. However, the effect of this and similar drugs on HSCT outcomes is unknown, and the reports on their efficacy and safety in the peri-transplantation period vary widely in the published literature. This paper reviews clinical data related to the use of JAK inhibitors in the peri-implantation phase of hematopoietic stem cell transplantation for primary myelofibrosis and discusses their efficacy and safety.
引用
收藏
页码:3293 / 3301
页数:9
相关论文
共 68 条
[1]   Insights into the role of the JAK/STAT signaling pathway in graft-versus-host disease [J].
Abboud, Ramzi ;
Choi, Jaebok ;
Ruminski, Peter ;
Schroeder, Mark A. ;
Kim, Sena ;
Abboud, Camille N. ;
DiPersio, John F. .
THERAPEUTIC ADVANCES IN HEMATOLOGY, 2020, 11
[2]   Effects of spleen status on early outcomes after hematopoietic cell transplantation [J].
Akpek, G. ;
Pasquini, M. C. ;
Logan, B. ;
Agovi, M-A ;
Lazarus, H. M. ;
Marks, D. I. ;
Bornhaeueser, M. ;
Ringden, O. ;
Maziarz, R. T. ;
Gupta, V. ;
Popat, U. ;
Maharaj, D. ;
Bolwell, B. J. ;
Rizzo, J. D. ;
Ballen, K. K. ;
Cooke, K. R. ;
McCarthy, P. L. ;
Ho, V. T. .
BONE MARROW TRANSPLANTATION, 2013, 48 (06) :825-831
[3]   Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label study [J].
Ali, Haris ;
Tsai, Ni-Chun ;
Synold, Timothy ;
Mokhtari, Sally ;
Tsia, Weimin ;
Palmer, Joycelynne ;
Stiller, Tracey ;
Al Malki, Monzr ;
Aldoss, Ibrahim ;
Salhotra, Amandeep ;
Rahmanuddin, Syed ;
Pullarkat, Vinod ;
Cai, Ji-Lian ;
Stein, Anthony ;
Forman, Stephen J. ;
Marcucci, Guido ;
Mei, Matthew ;
Snyder, David S. ;
Nakamura, Ryotaro .
BLOOD ADVANCES, 2022, 6 (05) :1444-1453
[4]   Outcome of Transplantation for Myelofibrosis [J].
Ballen, Karen K. ;
Shrestha, Smriti ;
Sobocinski, Kathleen A. ;
Zhang, Mei-Jie ;
Bashey, Asad ;
Bolwell, Brian J. ;
Cervantes, Francisco ;
Devine, Steven M. ;
Gale, Robert Peter ;
Gupta, Vikas ;
Hahn, Theresa E. ;
Hogan, William J. ;
Kroeger, Nicolaus ;
Litzow, Mark R. ;
Marks, David I. ;
Maziarz, Richard T. ;
McCarthy, Philip L. ;
Schiller, Gary ;
Schouten, Harry C. ;
Roy, Vivek ;
Wiernik, Peter H. ;
Horowitz, Mary M. ;
Giralt, Sergio A. ;
Arora, Mukta .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2010, 16 (03) :358-367
[5]   JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects [J].
Banerjee, Shubhasree ;
Biehl, Ann ;
Gadina, Massimo ;
Hasni, Sarfaraz ;
Schwartz, Daniella M. .
DRUGS, 2017, 77 (05) :521-546
[6]   Thiotepa-busulfan-fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT [J].
Battipaglia, Giorgia ;
Mauff, Katya ;
Wendel, Lotus ;
Angelucci, Emanuele ;
Mohty, Mohamad ;
Arcese, William ;
Santarone, Stella ;
Rubio, Marie Therese ;
Kroger, Nicolaus ;
Fox, Maria Laura ;
Blaise, Didier ;
Iori, Anna Paola ;
Fanin, Renato ;
Chalandon, Yves ;
Pioltelli, Pietro ;
Marotta, Giuseppe ;
Chiusolo, Patrizia ;
Sever, Matjaz ;
Solano, Carlos ;
Contentin, Nathalie ;
de Wreede, Liesbeth C. ;
Czerw, Tomasz ;
Hernandez-Boluda, Juan Carlos ;
Hayden, Patrick ;
McLornan, Donal ;
Yakoub-Agha, Ibrahim .
BONE MARROW TRANSPLANTATION, 2021, 56 (07) :1593-1602
[7]   Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms [J].
Berdeja, J. ;
Palandri, F. ;
Baer, M. R. ;
Quick, D. ;
Kiladjian, J. J. ;
Martinelli, G. ;
Verma, A. ;
Hamid, O. ;
Walgren, R. ;
Pitou, C. ;
Li, P. L. ;
Gerds, A. T. .
LEUKEMIA RESEARCH, 2018, 71 :82-88
[8]   Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiation [J].
Betts, Brian C. ;
Bastian, David ;
Iamsawat, Supinya ;
Hung Nguyen ;
Heinrichs, Jessica L. ;
Wu, Yongxia ;
Daenthanasanmak, Anusara ;
Veerapathran, Anandharaman ;
O'Mahony, Alison ;
Walton, Kelly ;
Reff, Jordan ;
Horna, Pedro ;
Sagatys, Elizabeth M. ;
Lee, Marie C. ;
Singer, Jack ;
Chang, Ying-Jun ;
Liu, Chen ;
Pidala, Joseph ;
Anasetti, Claudio ;
Yu, Xue-Zhong .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2018, 115 (07) :1582-1587
[9]   Baricitinib-induced blockade of interferon gamma receptor and interleukin-6 receptor for the prevention and treatment of graft versus-host disease [J].
Choi, Jaebok ;
Cooper, Matthew L. ;
Staser, Karl ;
Ashami, Kidist ;
Vij, Kiran R. ;
Wang, Bing ;
Marsala, Lynne ;
Niswonger, Jessica ;
Ritchey, Julie ;
Alahmari, Bader ;
Achilefu, Samuel ;
Tsunoda, Ikuo ;
Schroeder, Mark A. ;
DiPersio, John F. .
LEUKEMIA, 2018, 32 (11) :2483-2494
[10]   Pharmacologic Blockade of JAK1/JAK2 Reduces GvHD and Preserves the Graft-Versus-Leukemia Effect [J].
Choi, Jaebok ;
Cooper, Matthew L. ;
Alahmari, Bader ;
Ritchey, Julie ;
Collins, Lynne ;
Holt, Matthew ;
DiPersio, John F. .
PLOS ONE, 2014, 9 (10)